Comparative glycosylation mapping of plasma-derived and recombinant human factor VIII

Human coagulation factor VIII (FVIII) is a key co-factor in the clotting cascade, the deficiency of which leads to Hemophilia A. Human plasma-derived (pdFVIII) and recombinant FVIII (rFVIII) had been used as effective products to prevent and treat bleeding episodes. Both FVIII products share identical amino acid sequences and appear to be equivalent as of clinical efficiency. However, systemic reviews found an increased risk of neutralizing antibody (or inhibitor) development with recombinant products. FVIII is a highly glycosylated protein, and its glycosylation pattern is specific to host cells and environments. The roles of glycosylation in immune responses toward pdFVIII and rFVIII are yet to be defined. Herein, we systemically profiled N- and O-glycomes of pdFVIII and rFVIII using a mass spectrometry-based glycoproteomic strategy. A total of 110 site-specific N-glycopeptides consisting of 61 N-glycoforms were identified quantitatively from rFVIII and pdFVIII. Additionally, 31 O-glycoforms were identified on 23 peptides from rFVIII and pdFVIII. A comprehensive comparison of their site-specific glycan profiles revealed distinct differences between the glycosylation of pdFVIII and rFVIII.

• Publication year

  2020

• Venue

  PLoS ONE

• Publication date

  2020-05-22

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1371/journal.pone.0233576PMID 32442215PMCID 7244179
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Advances in knowledge of inhibitor formation in severe haemophilia A

  2020cited by this paper
• Peptides identified on monocyte-derived dendritic cells: a marker for clinical immunogenicity to FVIII products.

  2019cited by this paper
• Increased branching and sialylation of N-linked glycans correlate with an improved pharmacokinetic profile for BAY 81–8973 compared with other full-length rFVIII products

  2019cited by this paper
• In‐depth comparison of N‐glycosylation of human plasma‐derived factor VIII and different recombinant products: from structure to clinical implications

  2018cited by this paper
• Impact of host cell line choice on glycan profile

  2018cited by this paper
• N-linked glycosylation modulates the immunogenicity of recombinant human factor VIII in hemophilia A mice

  2018cited by this paper
• Carbohydrate structure: the rocky road to automation.

  2017cited by this paper
• Alpha‐gal is a possible target of IgE‐mediated reactivity to antivenom

  2017cited by this paper
• Characterizing the O-glycosylation landscape of human plasma, platelets, and endothelial cells.

  2017cited by this paper
• N-glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and Fc fusion proteins.

  2016cited by this paper
• A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A.

  2016cited by this paper
• Challenges of glycosylation analysis and control: an integrated approach to producing optimal and consistent therapeutic drugs.

  2016cited by this paper
• BAY 81‐8973, a full‐length recombinant factor VIII: results from an International comparative laboratory field study

  2016cited by this paper
• Characterization of Missense Mutations in Factor VIII That Lead to Abnormal N-Linked Glycosylation

  2016cited by this paper
• A precise approach in large scale core-fucosylated glycoprotein identification with low- and high-normalized collision energy.

  2015cited by this paper
• N‐linked glycoproteome profiling of human serum using tandem enrichment and multiple fraction concatenation

  2013cited by this paper
• Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII.

  2013cited by this paper
• Factor VIII inhibitors: a 50‐year perspective

  2011cited by this paper
• Improved peptide identification by targeted fragmentation using CID, HCD and ETD on an LTQ-Orbitrap Velos.

  2011cited by this paper
• High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans.

  2011cited by this paper
• Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins

  2010cited by this paper
• Purification and characterization of a new recombinant factor VIII (N8)

  2010cited by this paper
• Combination of FASP and StageTip-based fractionation allows in-depth analysis of the hippocampal membrane proteome.

  2009cited by this paper
• Effects of glycosylation on the stability of protein pharmaceuticals.

  2009cited by this paper
• Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice.

  2009cited by this paper
• Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC

  2008cited by this paper
• GlycoWorkbench: a tool for the computer-assisted annotation of mass spectra of glycans.

  2008cited by this paper
• A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes

  2007cited by this paper
• VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors.

  2007cited by this paper
• Structure and Function of the Factor VIII Gene and Protein

  2003cited by this paper
• Pathophysiology of inhibitors to factor VIII in patients with haemophilia A

  2002cited by this paper
• The hemophilias--from royal genes to gene therapy.

  2001cited by this paper
• Glycosylation of Pichia pastoris ‐derived proteins

  1999cited by this paper
• Structural characterization of site-specific N-glycosylation of recombinant human factor VIII by reversed-phase high-performance liquid chromatography-electrospray ionization mass spectrometry.

  1997cited by this paper
• Detailed peptide characterization using PEPTIDEMASS – a World‐Wide‐Web‐accessible tool

  1997cited by this paper
• Comparative study of the sugar chains of factor VIII purified from human plasma and from the culture media of recombinant baby hamster kidney cells.

  1992cited by this paper
• The Increasing Prevalence of Haemophilia

  1990cited by this paper
• The Complex Carbohydrate Structure Database.

  1989cited by this paper
• The physiology and pathophysiology of the factor VIII complex.

  1986cited by this paper
• Factor VIII: Structure and function in blood clotting

  1984cited by this paper

• Transplanted gene-modified placental cells boost FVIII activity in pediatric sheep without eliciting immunity, toxicity, or adverse events

  2026cites this paper
• Factor VIII a coagulation co-factor is a relevant survival factor in bladder cancer cell lines.

  2025cites this paper
• Exploration of biomarkers for inhibitor development in persons with hemophilia A

  2025cites this paper
• Impact of Inhibitor Development on the Cost Effectiveness of Prophylactic Treatment with Recombinant Factor VIII in Previously Untreated Patients with Severe Hemophilia A.

  2025cites this paper
• Coagulation Factor VIII: Biological Basis of Emerging Hemophilia A Therapies.

  2024cites this paper
• Advances in biopharmaceutical products for hemophilia

  2024cites this paper
• Dendritic Mesoporous Organosilica Nanoparticles with Photosensitizers for Cell Imaging, siRNA Delivery and Protein Loading

  2023cites this paper
• Enhancing pharmacokinetic and pharmacodynamic properties of recombinant therapeutic proteins by manipulation of sialic acid content.

  2023cites this paper
• Coagulation abnormalities in a prospective cohort of 50 patients with PMM2-congenital disorder of glycosylation.

  2023cites this paper
• Modulation of factor VIII pharmacokinetics by genetic components in factor VIII receptors

  2022cites this paper
• Combination of CLEC4M rs868875 G-Carriership and ABO O Genotypes May Predict Faster Decay of FVIII Infused in Hemophilia A Patients

  2022cites this paper
• Influence of N-glycosylation in the A and C domains on the immunogenicity of factor VIII

  2022cites this paper
• O-glycosylation and its role in therapeutic proteins

  2022cites this paper
• Autologous bone marrow-derived MSCs engineered to express oFVIII-FLAG engraft in adult sheep and produce an effective increase in plasma FVIII levels

  2022cites this paper
• Characterization of protein unable to bind von Willebrand factor in recombinant factor VIII products

  2021cites this paper
• Removal of single‐site N‐linked glycans on factor VIII alters binding of domain‐specific monoclonal antibodies

  2021cites this paper
• The Asialoglycoprotein Receptor Minor Subunit Gene Contributes to Pharmacokinetics of Factor VIII Concentrates in Hemophilia A

  2021cites this paper
• Determination of modification degree of polysialylated therapeutic proteins using 1H-NMR spectroscopy.

  2021cites this paper
• Site-Specific N- and O-Glycosylation Analysis of Human Plasma Fibronectin

  2021cites this paper